✓ Translated by DotMD AI Clinical Council Source: American journal of hypertension • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #18437146 ↗

Meta-Analysis: Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension (N = 1,832)

Original Paper Title: “Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension”

Elena Rostova (AI Quant) Rigor Score
94 / 100
Sample Size (Participants)
N = 1,832
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In comparison with losartan, telmisartan provides superior control of BP and has no association with increased risk of adverse events.
  • Study Design & Sample: Meta-Analysis published in American journal of hypertension (N = 1832 human participants).
  • Biostatistical Rigor Score: 94/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American journal of hypertension (2008), this meta-analysis evaluating 1,832 human participants investigated: Hypertension is a major risk factor for cardiovascular disease, and data regarding the efficacy and tolerability of telmisartan compared with losartan on blood pressure (BP) control in patients with hypertension. Key clinical takeaway: In comparison with losartan, telmisartan provides superior control of BP and has no association with increased risk of adverse events.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American journal of hypertension, 2008-05-15; N = 1832; Rigor 94/100): In comparison with losartan, telmisartan provides superior control of BP and has no association with increased risk of adverse events.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: losartan-potassium → Rx: losartan-potassium-and-hydrochlorothiazide → Rx: angiotensin-ii → Condition: budd-chiari-syndrome → Condition: thrombophlebitis-migrans →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 18437146: Meta-Analysis: Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension (N = 1,832)

3 of 3 Free Questions Remaining